Newsletter | October 8, 2025

10.08.25 -- Australia's R&D Incentive: Not A Gift, But A Tax Strategy

SPONSOR

DECENTRALIZED TRIALS

Bridging Community And Central Hospitals With Japan's DCT Model

Regulatory support and improved DCT infrastructure, as well as a uniquely Japanese approach to site relationships, are advancing the DCT landscape in Japan, explains consultant Takuma Matsunaga.

Inspection Readiness For Decentralized Trials

Decentralized Clinical Trials (DCTs) enhance research inclusivity by minimizing logistical barriers such as travel, scheduling conflicts, and costs, making participation more accessible.

SPONSOR

Join Clinical Leader on October 23 at 1PM ET for a virtual panel discussion on FSO or FSP? What Works, When, and Why. Registration is free with support from Catalyst Flex.

TRIAL MANAGEMENT

Australia's R&D Incentive: Not A Gift, But A Tax Strategy

Mike Burfield explains that the 43.5% R&D incentive is often misunderstood as free money. In reality, it’s a tax program requiring eligible entities, deductible R&D spend, and clear paths to revenue. Foreign sponsors must align tax, corporate, and transfer-pricing rules to benefit.

Designing An Optimal APAC Clinical Supply Chain

Gain the knowledge and skills needed to effectively navigate the complex clinical supply distribution landscape within this important and rapidly growing region.

Advancing Alzheimer's Disease Therapies

By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.

Clinical Trial Marketing And Advertising: Best Practices For 2025

Adopting innovative strategies can significantly improve patient recruitment, accelerate trials, and support the development of new therapies.

Factors Affecting Systemic Drug Exposure

The increasing number of drugs on the market leads to a greater potential for DDIs. Determining the extent of the interaction and associated risks is an important safety consideration.

The Untapped Power Of Real-World Data And AI In Pharma Commercialization

Harnessing RWD in commercialization bridges the gap between approval and patient access, equipping companies with actionable intelligence to deliver life-changing therapies to more patients.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: